ClearBrook Imaging
ClearBrook Imaging is a specialty,
development-stage, medical device company whose primary focus is developing its
intravascular photoacoustic cardiac catheterization imaging technology, which
addresses the shortcomings of existing modalities in the cardiac
catheterization industry. ClearBrook's Intravascular Photoacoustic (IVPA)
catheter is a revolutionary imaging technology capable of providing
interventional cardiologists with the necessary information they need to properly
diagnose atherosclerosis and plaque vulnerability.
Cardiovascular disease (CVD) is the most common cause of death in the world, claiming over 830,000 lives annually in the US alone. This means that almost 2,500 Americans die of CVD each day, which is an average of one death every 35 seconds. This rate is higher than the next four leading causes of death combined (cancer, diabetes mellitus, accidents, and chronic lower respiratory diseases).
The most prevalent form of CVD is coronary artery disease (CAD), which accounts for over half of CVD deaths, and is the single leading cause of death globally. Coronary artery atherosclerosis, the clogging or hardening of arteries or blood vessels caused by plaques, is the principal contributor to coronary artery disease (CAD) and plaque vulnerability. Plaque vulnerability is the main cause of deaths from CAD.
To treat coronary artery atherosclerosis and plaque vulnerability, interventional cardiologists perform a procedure called percutaneous coronary intervention (PCI). During a PCI, a cardiologist inserts a stent into the patient’s body to open up restricted blood flow. The problem with this procedure is that recent studies have shown that stent thrombosis, a life-threatening blood clot, occurs in as much as 2% of all PCI procedures due to improper stent placement. This error occurs because of the shortcomings of current imaging techniques used to diagnose vulnerable plaque and for stent placement. ClearBrook’s IVPA catheter is a groundbreaking solution to this problem.
Cardiovascular disease (CVD) is the most common cause of death in the world, claiming over 830,000 lives annually in the US alone. This means that almost 2,500 Americans die of CVD each day, which is an average of one death every 35 seconds. This rate is higher than the next four leading causes of death combined (cancer, diabetes mellitus, accidents, and chronic lower respiratory diseases).
The most prevalent form of CVD is coronary artery disease (CAD), which accounts for over half of CVD deaths, and is the single leading cause of death globally. Coronary artery atherosclerosis, the clogging or hardening of arteries or blood vessels caused by plaques, is the principal contributor to coronary artery disease (CAD) and plaque vulnerability. Plaque vulnerability is the main cause of deaths from CAD.
To treat coronary artery atherosclerosis and plaque vulnerability, interventional cardiologists perform a procedure called percutaneous coronary intervention (PCI). During a PCI, a cardiologist inserts a stent into the patient’s body to open up restricted blood flow. The problem with this procedure is that recent studies have shown that stent thrombosis, a life-threatening blood clot, occurs in as much as 2% of all PCI procedures due to improper stent placement. This error occurs because of the shortcomings of current imaging techniques used to diagnose vulnerable plaque and for stent placement. ClearBrook’s IVPA catheter is a groundbreaking solution to this problem.
